All In Biotech

Drug Trial Radar · NCT02124278

Safety and Tolerability of Single Ascending Doses of PUL-042 Inhalation Solution in Healthy Subjects

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PUL-042 Inhalation Solution in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 29, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

42

Actual

Start

Feb 2014

Primary completion

Oct 2014

Study completion Oct 2014

Sponsor

Lead sponsor
Pulmotect, Inc.Industry
Sponsor type
Industry
First posted
Apr 28, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose is to determine if single doses of PUL-042 inhalation solution are safe in healthy subjects.

Conditions

  • Healthy

Interventions

  • PUL-042 Inhalation SolutionDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting toxicities (DLTs)Time frame: Dosing to one week post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Development Solutions

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.